Unravel Biosciences utilizes AI-driven analysis of patient RNA signatures to identify therapeutic mechanisms and drug targets for complex disorders, significantly reducing the time required for drug development. By leveraging existing drugs' off-target effects, the platform enables rapid clinical validation of new treatments, addressing the urgent need for effective therapies in patients with rare and complex diseases.
Funding
$550K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
MGFounders
Product
Problem
Drug development for complex disorders is a lengthy and expensive process, often taking many years and requiring significant investment. Identifying effective therapeutic mechanisms and drug targets can be challenging, particularly for rare and heterogeneous diseases, leading to delays in bringing new treatments to patients.
Solution
Unravel Biosciences uses an AI-driven platform that analyzes patient RNA signatures to identify therapeutic mechanisms and drug targets for complex disorders. The platform leverages a proprietary foundation model of human health and systems biology to build in-silico networks from patient data, enabling the rapid identification of potential treatments. By focusing on the off-target effects of existing drugs, Unravel Biosciences aims to accelerate clinical validation and deliver effective therapies to patients with unmet needs more quickly and efficiently. The company's approach allows for the clinical derisking of new targets using existing drugs, reducing the time and cost associated with traditional drug development.
Target Audience
The primary target audience includes pharmaceutical companies, research institutions, and clinicians focused on developing treatments for rare and complex disorders with high unmet needs.
Features
- AI-driven analysis of patient RNA signatures to identify therapeutic mechanisms
- Proprietary foundation model of human health and systems biology
- In-silico network construction for target discovery
- Identification of existing drugs with off-target effects for rapid clinical validation
- Patient stratification by drug response
- Development of animal models for efficacy and safety testing
- RNAseq home collection kit for patients with limited data availability